The value of a three-microRNA panel in serum for prostate cancer screening.

IF 2.3 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

International Journal of Biological Markers Pub Date : 2024-03-01 Epub Date: 2023-11-13 DOI:10.1177/03936155231213660

Shengjie Lin, Chen Sun, Rongkang Li, Chong Lu, Xinji Li, Zhenyu Wen, Zhenjian Ge, Wenkang Chen, Yingqi Li, Hang Li, Yongqing Lai

{"title":"The value of a three-microRNA panel in serum for prostate cancer screening.","authors":"Shengjie Lin, Chen Sun, Rongkang Li, Chong Lu, Xinji Li, Zhenyu Wen, Zhenjian Ge, Wenkang Chen, Yingqi Li, Hang Li, Yongqing Lai","doi":"10.1177/03936155231213660","DOIUrl":null,"url":null,"abstract":"Background: Globally, prostate cancer is the second most common malignancy in males. Serum microRNAs (miRNAs) may function as non-invasive and innovative biomarkers for various cancers. Our study aimed to determine potential miRNAs for prostate cancer screening.Methods: A three-stage study was accomplished to ascertain crucial miRNAs as markers. In the screening stage, we searched PubMed for aberrantly expressed miRNAs relevant to prostate cancer and selected them as candidate miRNAs. In training and validation stages, with serum specimens from 112 prostate cancer patients and 112 healthy controls, expressions of candidate miRNAs were identified through quantitative reverse transcription-polymerase chain reaction. The diagnostic capabilities of miRNAs were determined by receiver operating characteristic curves. Bioinformatic analysis was utilized to explore the function of the critical miRNAs.Results: Expression of six serum miRNAs (miR-34b-3p, miR-556-5p, miR-200c-3p, miR-361-5p, miR-369-3p, miR-485-3p) were significantly altered in prostate cancer patients contrasted with healthy controls. The optimal combination of critical miRNAs is a three-miRNA panel (miR-34b-3p, miR-200c-3p, and miR-361-5p) with good diagnostic capability. FLRT2, KIAA1755, LDB3, and NTRK3 were identified as the potential genes targeted by the three-miRNA panel.Conclusions: The three-miRNA panel may perform as an innovative and promising serum marker for prostate cancer screening.","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":" ","pages":"70-79"},"PeriodicalIF":2.3000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Biological Markers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03936155231213660","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/13 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Globally, prostate cancer is the second most common malignancy in males. Serum microRNAs (miRNAs) may function as non-invasive and innovative biomarkers for various cancers. Our study aimed to determine potential miRNAs for prostate cancer screening.

Methods: A three-stage study was accomplished to ascertain crucial miRNAs as markers. In the screening stage, we searched PubMed for aberrantly expressed miRNAs relevant to prostate cancer and selected them as candidate miRNAs. In training and validation stages, with serum specimens from 112 prostate cancer patients and 112 healthy controls, expressions of candidate miRNAs were identified through quantitative reverse transcription-polymerase chain reaction. The diagnostic capabilities of miRNAs were determined by receiver operating characteristic curves. Bioinformatic analysis was utilized to explore the function of the critical miRNAs.

Results: Expression of six serum miRNAs (miR-34b-3p, miR-556-5p, miR-200c-3p, miR-361-5p, miR-369-3p, miR-485-3p) were significantly altered in prostate cancer patients contrasted with healthy controls. The optimal combination of critical miRNAs is a three-miRNA panel (miR-34b-3p, miR-200c-3p, and miR-361-5p) with good diagnostic capability. FLRT2, KIAA1755, LDB3, and NTRK3 were identified as the potential genes targeted by the three-miRNA panel.

Conclusions: The three-miRNA panel may perform as an innovative and promising serum marker for prostate cancer screening.

查看原文本刊更多论文

血清中三微小核糖核酸检测对前列腺癌筛查的价值。

背景:在全球范围内，前列腺癌是男性第二常见的恶性肿瘤。血清microRNAs (miRNAs)可作为多种癌症的非侵入性和创新性生物标志物。我们的研究旨在确定前列腺癌筛查的潜在mirna。方法:完成了三个阶段的研究，以确定关键的mirna作为标记。在筛选阶段，我们在PubMed中搜索与前列腺癌相关的异常表达mirna，并将其作为候选mirna。在训练和验证阶段，利用112名前列腺癌患者和112名健康对照者的血清标本，通过定量逆转录-聚合酶链反应鉴定候选mirna的表达。mirna的诊断能力由受试者工作特征曲线确定。利用生物信息学分析来探索关键mirna的功能。结果:与健康对照组相比，前列腺癌患者血清中6种mirna (miR-34b-3p、miR-556-5p、miR-200c-3p、miR-361-5p、miR-369-3p、miR-485-3p)的表达显著改变。关键mirna的最佳组合是具有良好诊断能力的三mirna面板(miR-34b-3p, miR-200c-3p和miR-361-5p)。FLRT2、KIAA1755、LDB3和NTRK3被确定为3 - mirna小组的潜在靶向基因。结论:3 - mirna小组可能作为前列腺癌筛查的一种创新和有前途的血清标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Biological Markers 医学-生物工程与应用微生物

CiteScore

4.10

自引率

0.00%

发文量

期刊介绍： IJBM is an international, online only, peer-reviewed Journal, which publishes original research and critical reviews primarily focused on cancer biomarkers. IJBM targets advanced topics regarding the application of biomarkers in oncology and is dedicated to solid tumors in adult subjects. The clinical scenarios of interests are screening and early diagnosis of cancer, prognostic assessment, prediction of the response to and monitoring of treatment.